Pathogenetic mechanisms in phenylketonuria: Disorders affecting the metabolism of neurotransmitters and the antioxidant system;Mecanismos de patogenia en la fenilcetonuria: Alteraciones del metabolismo de los neurotransmisores y del sistema antioxidante

Revista de Neurologia

Volumn 39, Issue 10, 2004, Pages 956-961

  Ormazabal A ^a   Artuch, Rafael ^a,b   Vilaseca, M A ^a   Garcia Cazorla A ^a   Campistol, J ^a  

^a HOSPITAL SANT JOAN DE DÉU   (Spain)

^b HospitalSant Joan de Dén   (Spain)

Author keywords

Antioxidant system; Dietary treatment; Neurotransmitters; Phenylketonuria; Tetrahydrobiopterin

Indexed keywords

DOPAMINE; NEUROTRANSMITTER; PHENYLALANINE; PHENYLALANINE 4 MONOOXYGENASE; SEROTONIN; TYROSINE;

AMINO ACID BLOOD LEVEL; AMINO ACID SYNTHESIS; ANTIOXIDANT ACTIVITY; BIOSYNTHESIS; BRAIN METABOLISM; CLINICAL FEATURE; DIET THERAPY; DISEASE COURSE; ENZYME ACTIVITY; HUMAN; HYPERPHENYLALANINEMIA; INBORN ERROR OF METABOLISM; NEUROTRANSMISSION; NONHUMAN; PATHOPHYSIOLOGY; PHENYLKETONURIA; REVIEW; TISSUE LEVEL;

EID: 10444222972     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3910.2004221     Document Type: Review

References (36)

1. Scriver CR, Kaufman S, Eisensmith RC, Woo SLS. The hyperphenylalaninemia. In Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill; 1995. p. 1015-75.
2. Van Spronsen FJ, Smit PGA, Koch R. Phenylketonuria: tyrosine beyond the phenylalanine-restricted diet. J Inherit Metab Dis 2001; 24: 1-4.
3. Vilaseca MA, Briones P, Ferrer I, Campistol J, Riverola A, Castillo P, et al. Controlled diet in phenylketonuria may cause serum carnitine deficiency. J Inherit Metab Dis 1993; 13: 101-4.
4. Przyrembel H, Bremer HJ. Nutrition, physical growth, and bone density in treated phenylketonuria. Eur J Pediatr 2000; 159: 129-35.
5. Campistol J, Lambruschini N, Vilaseca MA, Cambra FJ, Fusté E, Gómez L. Hiperfenilalaninemias. In Sanjunjo P, Baldellou A, eds. Diagnóstico y tratamiento de las enfermedades metabólicas hereditarias. Madrid: Ergon; 2001. p. 195-206.
6. Nielsen JB, Lou HC, Güttler F. Effects of diet discontinuation and dietary tryptophan supplementation on neurotransmitter metabolism in phenylketonuria. Brain Dysfunction 1988; 1: 51-6.
7. Smith I, Beasley MG, Ades AE. Intelligence and quality of dietary treatment in phenylketonuria. Arch Dis Child 1990; 65: 472-8.
8. Wappner R, Cho S, Kronmal RA, Schuett V, Seashore MR. Management of phenylketonuria for optimal outcome: a review of guidelines for phenylketonuria management and a report of surveys of parents, patients and clinic directors. Pediatrics 1999; 104: 68.
9. Surtees R, Blau N. The neurochemistry of phenylketonuria. Eur J Pediatr 2000; 159 (Suppl 2): S109-13.
10. Pardridge WM. Blood-brain barrier carrier mediated transport and brain metabolism of amino acids. Neurochem Res 1998; 23: 635-44.
11. Burlina AB, Bonafé L, Ferrari V, Suppiej A, Zacchello F, Burlina AP. Measurement of neurotransmitter metabolites in the cerebrospinal fluid of phenylketonuric patients under dietary treatment. J Inherit Metab Dis 2000; 23: 313-6.
12. Puglisi-Allegra S, Cabib S, Pascucci T, Ventura R, Calì F, Romano V. Dramatic brain aminergic déficit in a genetic mouse model of phenylketonuria. Neurochemistry 2000; 11: 1361-4.
13. Acosta PB. Nutrition studies in treated infants and children with phenylketonuria: vitamins, minerals, trace elements. Eur J Pediatr 1996; 155: 136-9.
14. Kinzle-Hagen ME, Pederzolli CD, Sgaravatti AM, Bridi R, Wajner M, Wannmacher CMD, et al. Experimental hyperphenylalaninemia provokes oxidative stress in rat brain. Biochim Biophys Acta 2002; 1586: 344-52.
15. Grace AA, Gerfen CR, Aston-Jones G. Catecholamines in the central nervous system: overview. Adv Pharmacol 1998; 42: 655.
16. Kaufman S. Regulatory properties of pterin dependent hydroxylases: variation on a theme. In Usdin E, Weiner N, Youdim MBH, eds. Function and regulation of monoamine enzymes. New-York: Macmillan; 1981. p. 165.
17. Lou HC, Lykkelund C, Verdes AM, Udesen H, Bruhn P. Increased vigilance and dopamine synthesis by large doses of tyrosine or phenylalanine restriction in phenylketonuria. Acta Paediatr Scand 1987; 76: 560-5.
18. Koch R, Moseley KD, Yano S, Nelson M, Moats RA. Large neutral amino acid therapy and phenylketonuria: a promising approach to treatment. Mol Genet Metab 2003; 79: 110-3.
19. Pascucci T, Ventura R, Puglisi-Allegra S, Cabib S. Deficits in brain serotonine synthesis in a genetic mouse model of phenylketonuria. Clin Neurosci Neuropsychol 2002; 13: 2561-4.
20. Davies KJA. Oxidative stress: the paradox of aerobic life. In Rice-Evans C, Halliwell B, Lunt GG, ed. Free radicals and oxidative stress: environment, drugs and food additives. London: Portland Press; 1995. p. 1-32.
21. Gabsi S, Gouider-Khouja N, Belal S, Fki M, Kefi M, Turki I, et al. Effect of vitamin E supplementation in patients with ataxia with vitamin E deficiency. Eur J Neurol 2001; 8: 477-81.
22. Colomé C, Sierra C, Vilaseca MA. Errores congénitos del metabolismo: ¿causa de estrés oxidativo? Med Clin (Barc) 2000; 115: 111-7.
23. Lombeck I, Jochum F, Terwolbeck K. Selenium status in infants and children with phenylketonuria and in maternal phenylketonuria. Eur J Pediatr 1996; 155: 140-4.
24. Sierra C, Vilaseca MA, Moyano D, Brandi N, Campistol J, Lambruschini N, et al. Antioxidant status in hyperphenylalaninemia. Clin Chim Acta 1998; 276: 1-9.
25. Artuch R, Vilaseca MA, Moreno J, Lambruschini N, Cambra FJ, Campistol J. Decreased serum ubiquinone-10 concentration in phenylketonuria. Am J Clin Nutr 1999; 70: 892-5.
26. Colomé C, Artuch R, Vilaseca MA, Sierra C, Brandi N, Cambra FJ, et al. Ubiquinone-10 content in lymphocytes of phenylketonuric patients. Clin Biochem 2002; 35: 81-4.
27. Ernster L, Dallner G. Biochemical, physiological and medical aspects of ubiquinone function. Biochim Biophys Acta 1995; 1271: 195-204.
28. Artuch R, Colomé C, Vilaseca MA, Sierra C, Cambra FJ, Lambruschini N, et al. Plasma phenylalanine is associated with decreased serum ubiquinone-10 concentrations in phenylketonuria. J Inherit Metab Dis 2001; 24: 359-66.
29. Castillo M, Zafra MF, García-Peregrin E. Inhibition of brain and liver 3-hydroxy-3-methylglutaril coenzime A and mevalonate-5-pyrophosphate decarboxilase in experimental hyperphenylalaninemia. Neurochem Res 1988; 13: 551-5.
30. Colomé C, Artuch R, Vilaseca MA, Sierra C, Brandi N, Cambra FJ, et al. Lipophilic antioxidants in phenylketonuric patients. Am J Clin Nutr 2003; 77: 185-8.
31. Artuch R, Colomé C, Sierra C, Brandi N, Lambruschini N, Campistol J, et al. A longitudinal study of antioxidant status in phenylketonuric patients. Clin Biochem 2004; 37: 198-203.
32. Blau N, Scriver CR. New approaches to treat PKU: how far are we? Mol Genet Metab 2004; 81: 1-2.
33. Blau N, Thöny B, Cotton R, Hyland K. Disorders of tetrahydrobiopterin and relates biogenic amines. In Scriver C, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill; 2001. p. 1725-76.
34. Lindner M, Steinfeld R, Burgard P, Schulze A, Mayatepek E, Zschocke J. Tetrahydrobiopterin sensitivity in German patients with mild phenylalanine hydroxylase deficiency. Hum Mutat 2003; 21: 400.
35. Spaapen LJM, Rubio-Gozalbo ME. Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency, state of the art. Mol Genet Metab 2003; 78: 93-9.
36. Kure S, Hou DC, Ohura T, Iwamoto H, Suzuki S, Sugiyama N, et al. Tetrahydrobipoterin-responsive phenylalanine hydroxylase deficiency. J Pediatr 1999; 135: 375-8.